capecitabine + eribulin + gemcitabine + paclitaxel + albumin-bound paclitaxel

This drug entry refers to the Investigator's Choice of Chemotherapy (ICC) arm used as the active comparator in clinical trials conducted by Sichuan Baili Pharmaceutical Co., Ltd., most notably the Phase 3 trial (NCT06957886) for BL-M07D1 in HER2-low breast cancer. This regimen allows investigators to select one of five standard-of-care cytotoxic agents: capecitabine (an oral prodrug of 5-fluorouracil), eribulin (a non-taxane microtubule dynamics inhibitor), gemcitabine (a nucleoside analog), paclitaxel (a microtubule-stabilizing taxane), or albumin-bound paclitaxel (a nanoparticle formulation of paclitaxel). These agents employ distinct mechanisms—ranging from the inhibition of thymidylate synthase and DNA polymerase to the disruption of mitotic spindles—to treat unresectable, locally recurrent, or metastatic breast cancer.

Brand names

Abraxane

Other names

Investigator's Choice of ChemotherapyICC